How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement

Simply Wall St.06-11

In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642471153?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-06-11 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642471153","market":"hk","top_or_hot":-1,"title":"How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement","media":"Simply Wall St.","content":"<div>\n<p>In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-austedo-realworld-da\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 05:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-austedo-realworld-da><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-austedo-realworld-da\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-austedo-realworld-da","article_id":"2642471153","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-austedo-realworld-da","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642471153","pubTimestamp":1781126956,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and diagnosis rates when presented at Psych Congress Elevate in Las Vegas.\nThe findings, including real-world evidence from the IMPACT-TD Registry and long-term outcomes from the RIM-TD study, suggest that sustained treatment and caregiver education can meaningfully enhance recognition and management of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4559":"巴菲特持仓","BK4211":"区域性银行","BK4596":"哈里斯概念","ISBC":"投资者银行","BK4007":"制药","BK4557":"大麻股","BK4584":"避孕概念","BK4566":"资本集团","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","TEVA":"梯瓦制药"},"translate_title":"投资者对梯瓦(TEVA)AUSTEDO有关迟发性运动障碍改善的真实数据有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"TEVA":1.5},"content_text":"In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and diagnosis rates when presented at Psych Congress Elevate in Las Vegas. The findings, including real-world evidence from the IMPACT-TD Registry and long-term outcomes from the RIM-TD study, suggest that sustained treatment and caregiver education can meaningfully enhance recognition and management of this chronic movement disorder. We’ll now examine how Teva’s new real-world and long-term AUSTEDO data, particularly sustained TD improvement, could shape its investment narrative. Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementTeva Pharmaceutical Industries Investment Narrative RecapTo own Teva today, you need to believe its pivot toward higher margin branded drugs like AUSTEDO can offset a flat generics base while heavy debt is steadily reduced. The new AUSTEDO tardive dyskinesia data supports the product’s clinical profile, but it does not materially change the near term focus on AUSTEDO pricing risk under the Inflation Reduction Act or the need to keep improving cash flow to manage net debt above US$15 billion. Among recent announcements, the launch of AHZANTIVE, an Eylea biosimilar, in key European markets looks most connected to Teva’s broader growth story. It shows how biosimilars might support the generics segment, which consensus expects to remain flat, and could help diversify revenue away from the small group of branded drivers that currently concentrate Teva’s growth and regulatory risks. Yet, while the AUSTEDO data may support the bulls who see earnings rising toward US$3.1 billion, investors should also be aware of how... Read the full narrative on Teva Pharmaceutical Industries (it's free!)Teva Pharmaceutical Industries’ narrative projects $18.1 billion revenue and $2.7 billion earnings by 2029. This requires 1.5% yearly revenue growth and about a $1.1 billion earnings increase from $1.6 billion today.Uncover how Teva Pharmaceutical Industries' forecasts yield a $41.27 fair value, a 23% upside to its current price.Exploring Other PerspectivesTEVA 1-Year Stock Price Chart The most optimistic analysts were already assuming Teva could lift earnings to about US$3.1 billion by 2029, but this AUSTEDO update might either reinforce that view or highlight how dependent it is on one branded franchise that could face pricing and reimbursement pressure.Explore 3 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth just $41.27!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.Ready For A Different Approach?Opportunities like this don't last. These are today's most promising picks. Check them out now:Uncover the next big thing with 25 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.Outshine the giants: these 15 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642471153","isCrawlerRequest":true}